Babyl, Novo Nordisk partner to provide an innovative approach to diabetes awareness and care in Rwanda
{Babyl (NYSE: BBLN) and Novo Nordisk announced today that they have entered an innovative partnership to contribute to the expansion of diabetes awareness and care in Rwanda.}